Learn about the research from European Medicines Agency on the risks associated with the anti-obesity drug Acomplia in this medical report.
Read the full transcript »
Dr. Susan Sharma: This is insidermedicine in 60. From London, according to the European Medicines Agency, the risks associated with the anti-obesity drug Acomplia outweigh the benefit. Researchers examined evidence from ongoing clinical trials and found an increased risk for psychiatric disorders such as depression unacceptable, noting that the risk was double in those taking Acomplia. The agency recommends that doctors stop prescribing Acomplia and review the treatment of patients currently taking the drug. From Boston, according to research in the Journal of Pediatrics, smokers with ADHD are more susceptible to nicotine addiction. In a study of 80 patients with ADHD and 86 controls, researchers found that among ADHD patients, 69% had smoked at some point in their lifetime compared to 44% in the control group. In addition, 41% of ADHD patients were current smokers compared to only 17% of controls. And finally, from California, according to research in the Proceedings of the National Academy of Sciences, a compound found in many fruits and vegetables may increase the effectiveness of cancer treatments. The compound, a flavonoid called apigenin, was found to make cancer cells more vulnerable to chemotherapy drug in a lab dish. These findings may lead to new drugs modeled after this compound that could achieve the same effect clinically. For insidermedicine in 60, I'm Dr. Susan Sharma.